China Officially Charges GSK Executives, Details Bribery Practices
This article was originally published in PharmAsia News
Executive Summary
China’s Ministry of Public Security has made formal bribery charges against UK-based drug maker GlaxoSmithKline and former general manager Mark Reilly and two Chinese executives for bribing non-government agencies and personnel.
You may also be interested in...
China Regulatory Express: Biosecurity Law, Export Controls And The Life Science Sector
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Asia Deal Watch: Rhizen Licenses Chinese Rights For PI3K Inhibitor To Curon
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Asia Executives On The Move: Sanofi's Global R&D Head Moves To Innovent
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Need a specific report? 1000+ reports available
Buy Reports